Paper7543822
In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA and 6 others. Cancer Immunol Immunother, 1995. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody. Papers, record 7543822. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7543822
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antigens, CD | Major topic |
| Antigens, Differentiation, B-Lymphocyte | Major topic |
| B-Lymphocytes | Major topic |
| Animals | |
| Antigen-Antibody Reactions | |
| Antigens, CD19 | |
| Humans | |
| Idarubicin | |
| Immunity, Cellular | |
| Immunoconjugates | |
| Mice | |
| Mice, SCID | |
| Recombinant Fusion Proteins | |
| Tumor Cells, Cultured |
Source PubMed
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30693 | Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. | Immunochemistry | 1978 | https://conductscience.org/library/papers/30693 | PubMed |
| 2 | 3888313 | A clinical trial of anti-idiotype therapy for B cell malignancy. | Blood | 1985 | https://conductscience.org/library/papers/3888313 | PubMed |
| 3 | 3127726 | Reshaping human antibodies for therapy. | Nature | 1988 | https://conductscience.org/library/papers/3127726 | PubMed |
| 4 | 1568225 | Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2. | Cancer Res | 1992 | https://conductscience.org/library/papers/1568225 | PubMed |
| 5 | 7687521 | Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/7687521 | PubMed |
| 6 | 3464004 | Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. | Proc Natl Acad Sci U S A | 1986 | https://conductscience.org/library/papers/3464004 | PubMed |
| 7 | 8306242 | Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. | Cancer | 1994 | https://conductscience.org/library/papers/8306242 | PubMed |
| 8 | 8099991 | Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. | Lancet | 1993 | https://conductscience.org/library/papers/8099991 | PubMed |
| 9 | 2161448 | Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2161448 | PubMed |
| 10 | 8428365 | Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. | Cancer Res | 1993 | https://conductscience.org/library/papers/8428365 | PubMed |
| 11 | 4016762 | Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. | Cancer Res | 1985 | https://conductscience.org/library/papers/4016762 | PubMed |
| 12 | 2904526 | Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. | Lancet | 1988 | https://conductscience.org/library/papers/2904526 | PubMed |
| 13 | 1428411 | Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. | Int J Cancer Suppl | 1992 | https://conductscience.org/library/papers/1428411 | PubMed |
| 14 | 4549735 | Plasma cell surface antigen on human blood lymphocytes. | Nature | 1974 | https://conductscience.org/library/papers/4549735 | PubMed |
| 15 | 8327892 | Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. | Science | 1993 | https://conductscience.org/library/papers/8327892 | PubMed |
| 16 | 1373410 | Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. | Int J Cancer | 1992 | https://conductscience.org/library/papers/1373410 | PubMed |
| 17 | 1638557 | A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. | Cancer Immunol Immunother | 1992 | https://conductscience.org/library/papers/1638557 | PubMed |
| 18 | 7682986 | Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. | Immunology | 1993 | https://conductscience.org/library/papers/7682986 | PubMed |
| 19 | 8318495 | Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. | J Immunother Emphasis Tumor Immunol | 1993 | https://conductscience.org/library/papers/8318495 | PubMed |
| 20 | 942051 | A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. | Anal Biochem | 1976 | https://conductscience.org/library/papers/942051 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36264086 | Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models. | Oncotarget | 2022 | https://conductscience.org/library/papers/36264086 | PubMed |
| 35755944 | Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. | Mol Ther Methods Clin Dev | 2022 | https://conductscience.org/library/papers/35755944 | PubMed |
| 17665197 | Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. | Cancer Immunol Immunother | 2008 | https://conductscience.org/library/papers/17665197 | PubMed |
| 17495978 | A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. | Leukemia | 2007 | https://conductscience.org/library/papers/17495978 | PubMed |
| 17091246 | Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. | Springer Semin Immunopathol | 2006 | https://conductscience.org/library/papers/17091246 | PubMed |
| 16217038 | Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16217038 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7543822
GET https://conductscience.org/api/papers/v1/7543822/references?page=2